Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CCR5 | P51681 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525034 | 1.00 | LMNA (0.41) | LMNAPMP22NPSR1GFERCYP2D6 | |
| SCHEMBL6516899 | 0.93 | LMNA (0.45) | LMNAPMP22NPSR1GFERCYP2D6 | |
| SCHEMBL3177372 | 0.87 | CYP2C9 (0.38) | LMNAPMP22NPSR1GFERCYP2D6 | |
| SCHEMBL3177367 | 0.87 | CYP2C9 (0.38) | LMNAPMP22NPSR1GFERCYP2D6 | |
| SCHEMBL6516854 | 0.86 | KMT2A (0.46) | LMNAPMP22NPSR1GFERHDAC1 | |
| SCHEMBL6516859 | 0.86 | KMT2A (0.46) | LMNAPMP22NPSR1GFERHDAC1 | |
| SCHEMBL3459972 | 0.84 | HDAC1 (0.42) | LMNAPMP22NPSR1GFERCYP2D6 | |
| SCHEMBL3459969 | 0.84 | HDAC1 (0.42) | LMNAPMP22NPSR1GFERCYP2D6 | |
| SCHEMBL3459970 | 0.84 | HDAC1 (0.42) | LMNAPMP22NPSR1GFERCYP2D6 | |
| SCHEMBL17870841 | 0.83 | PIK3CD (0.42) | LMNAPIK3CDKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | claimed |
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2018-11-15 | — | — | US | claimed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | claimed |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200095229-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2020-03-26 | — | — | US | disclosed |
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3471718-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | Tobira Therapeutics, Inc. (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2018-11-15 | — | — | US | disclosed |
| WO-2017223155-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | disclosed |
| EP-1557669-A1 | Gas sensing material and gas inspecting method | FUJI PHOTO FILM CO., LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20050107606-A1 | Process for producing optically active sulfoxide derivative | TATKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1484322-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107606-A1 | Process for producing optically active sulfoxide derivative | CCR5, OPRM1, CXCR4 | LMNA 4466/4885PMP22 3390/4885NPSR1 320/4885 |
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | CCR5, CCR2, CCR3 | LMNA 3412/4885PMP22 3683/4885NPSR1 878/4885 |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | CCR5, CCR2, CCR3 | LMNA 3412/4885PMP22 3683/4885NPSR1 878/4885 |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | CCR5, CCR2, CXCR3 | LMNA 3225/4885PMP22 3335/4885NPSR1 2195/4885 |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | LMNA 3225/4885PMP22 3335/4885NPSR1 2195/4885 |
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | LMNA 3225/4885PMP22 3335/4885NPSR1 2195/4885 |
| US-20200095229-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | LMNA 3225/4885PMP22 3335/4885NPSR1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.